Bevacizumab Therapy for Brain Arteriovenous Malformation
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Arteriovenous malformations
- Focus Therapeutic Use
- 28 Feb 2020 Status changed from recruiting to completed.
- 30 Oct 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2022.
- 30 Oct 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2020.